Ventricular remodeling and heart failure after myocardial infarction: a community
心肌梗死后心室重构和心力衰竭:社区
基本信息
- 批准号:8607820
- 负责人:
- 金额:$ 74.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-15 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcuteAddressAdmission activityAffectBiologicalBiological MarkersCardiacCardiovascular DiseasesCharacteristicsCicatrixClinicalClinical TrialsCommunitiesComplexCoronaryCoronary heart diseaseDataDevelopmentDiagnosisDilatation - actionEFRACEducational workshopEpidemiologyEventExcess MortalityExtracellular MatrixFaceFrequenciesFunctional disorderFutureGoalsHeart failureHeterogeneityHospitalizationImageImaging TechniquesIncidenceInflammationInjuryInterventionKnowledgeLeft Ventricular RemodelingLeft atrial structureLeft ventricular structureMeasurementMeasuresMethodsMitral ValveMitral Valve InsufficiencyMorbidity - disease rateMuscle CellsMyocardialMyocardial InfarctionNational Heart, Lung, and Blood InstitutePathway interactionsPatientsPatternPersonsPopulationPopulation StudyPreventionProcessPublishingRecommendationRecoveryRecruitment ActivityResearchRiskRoleSamplingSeveritiesShapesStagingStressTestingThree-Dimensional EchocardiographyTimeTwo-Dimensional EchocardiographyVentricularVentricular DysfunctionVentricular Remodelingclinical applicationclinical practiceclinical riskclinically relevantcohortfibrogenesishigh riskimprovedindexinginnovationinsightmeetingsmenmortalitynovelpopulation basedpreventprospectivepublic health relevancetooltwo-dimensionalworking group
项目摘要
PROJECT SUMMARY/ABSTRACT
Over the past 2 decades, major changes in the epidemiology of myocardial infarction (MI) have occurred.
Progress in its acute treatment improved short term survival, but heart failure (HF) remains frequent after MI
and leads to excess mortality. Hence, the acute treatment of MI aimed at restoring vessel patency is not
sufficient to prevent HF, underscoring the importance of understanding the contemporary mechanisms leading
to its development. The transition from the initial myocardial injury to ventricular dysfunction and HF is termed
left ventricular remodeling and is characterized by progressive ventricular enlargement, alteration of systolic and
diastolic function and occurrence of mitral regurgitation (MR). Remodeling is a dynamic entity, defined as a
change over time, diagnosed at a stage where deleterious changes cannot be reversed. Hence, it must be
predicted and prevented. Knowledge on cardiac remodeling after MI is incomplete, which hinders its
prevention. Firstly, the exact incidence of remodeling remains to be defined as data pertain mostly to clinical
trials, of uncertain clinical relevance. Secondly, the mechanisms of ventricular remodeling after MI remain to
be defined with the goal of identifying novel predictors that could define targets for prevention and treatment.
Thirdly, most imaging data on remodeling do not reflect state of the art methods or contemporary cohorts.
Thus, addressing the frequency and mechanisms of remodeling after MI is needed to define strategies
to prevent HF and requires relying on clinically relevant populations evaluated by rigorous imaging
techniques integrated with measurements of novel biomarkers. Our 3 specific aims will help elucidate,
within a prospective community cohort, the frequency and mechanisms of ventricular remodeling and the
responsibilities of these mechanisms in the genesis of post MI HF. Aim 1 will measure the frequency and
patterns of left ventricular remodeling after incident MI in a community-based population. Remodeling
will be evaluated by two- and three-dimensional echocardiography and speckle tracking and defined as
changes in systolic or diastolic function and MR. Aim 2 will assess the determinants of remodeling,
including clinical characteristics and novel biomarkers. Aim 3 will test the value of the predictors of
remodeling identified in Aim 2 to predict HF after MI. In Aims 1 and 2, we will recruit 420 patients to obtain
serial two-dimensional and three-dimensional echocardiographic studies. Aim 3 will extend these findings to
the entire population-based MI incidence cohort. Our proposed application comprises several key innovative
aspects. Our ongoing surveillance of coronary disease will provide a strong recruitment platform and a robust
backdrop to optimize the clinical relevance of our data. Rigorous imaging approaches will provide unique
insights into the remodeling process. We will integrate imaging and biomarker data to identify predictors of
remodeling that can be measured at index MI to enable risk prediction of HF in contemporary MI populations.
项目总结/摘要
在过去的20年里,心肌梗死(MI)的流行病学发生了重大变化。
其急性治疗的进展改善了短期生存率,但心肌梗死后心力衰竭(HF)仍很常见
并导致死亡率过高。因此,旨在恢复血管通畅性的MI急性治疗并非
足以预防HF,强调了解当代机制的重要性,
它的发展。从最初的心肌损伤到心室功能障碍和HF的转变被称为
左心室重构,其特征在于进行性心室扩大、收缩和舒张功能的改变,
舒张功能和二尖瓣返流(MR)的发生。重构是一个动态实体,定义为
随着时间的推移而变化,在有害变化无法逆转的阶段诊断。因此,它必须
预测和预防。对心肌梗死后心脏重构的认识尚不完全,这阻碍了其治疗。
预防首先,重塑的确切发生率仍有待确定,因为数据主要涉及临床
临床相关性不确定的试验。其次,心肌梗死后心室重构的机制仍不清楚,
定义的目标是确定新的预测因子,可以确定预防和治疗的目标。
第三,大多数关于重塑的成像数据并不反映最先进的方法或当代队列。
因此,需要明确心肌梗死后重塑的频率和机制,以确定治疗策略
预防HF,需要依赖于通过严格成像评估的临床相关人群
与新的生物标志物的测量相结合的技术。我们的三个具体目标将有助于阐明,
在前瞻性社区队列中,心室重构的频率和机制以及
这些机制在MI后HF发生中的作用。目标1将测量频率,
社区人群中心肌梗死后左心室重构的模式。重塑
将通过二维和三维超声心动图和斑点追踪进行评价,并定义为
收缩或舒张功能和MR的变化。Aim 2将评估重塑的决定因素,
包括临床特征和新的生物标志物。目标3将测试以下预测因素的价值:
目的2中确定的重构预测MI后的HF。在目标1和2中,我们将招募420名患者,
系列二维和三维超声心动图研究。目标3将把这些发现扩展到
整个基于人群的MI发病率队列。我们提出的应用程序包括几个关键的创新
方面我们对冠状动脉疾病的持续监测将提供一个强大的招募平台和一个强大的
优化我们数据的临床相关性。严格的成像方法将提供独特的
对重塑过程的深入了解我们将整合成像和生物标志物数据,以确定
重构,可以在指数MI时测量,以预测当代MI人群中的HF风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAURICE ENRIQUEZ-SARANO其他文献
MAURICE ENRIQUEZ-SARANO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAURICE ENRIQUEZ-SARANO', 18)}}的其他基金
Therapeutic Strategy to slow progression of calcific aortic valve stenosis
减缓钙化性主动脉瓣狭窄进展的治疗策略
- 批准号:
8879241 - 财政年份:2014
- 资助金额:
$ 74.26万 - 项目类别:
Ventricular remodeling and heart failure after myocardial infarction: a community
心肌梗死后心室重构和心力衰竭:社区
- 批准号:
8977419 - 财政年份:2014
- 资助金额:
$ 74.26万 - 项目类别:
Therapeutic Strategy to slow progression of calcific aortic valve stenosis
减缓钙化性主动脉瓣狭窄进展的治疗策略
- 批准号:
8787182 - 财政年份:2013
- 资助金额:
$ 74.26万 - 项目类别:
Therapeutic Strategy to slow progression of calcific aortic valve stenosis
减缓钙化性主动脉瓣狭窄进展的治疗策略
- 批准号:
8598594 - 财政年份:2013
- 资助金额:
$ 74.26万 - 项目类别:
Therapeutic Strategy to slow progression of calcific aortic valve stenosis
减缓钙化性主动脉瓣狭窄进展的治疗策略
- 批准号:
8768834 - 财政年份:2013
- 资助金额:
$ 74.26万 - 项目类别:
MITRAL INSUFFICIENCY REDUCTION BY ANGIOTENSIN BLOCKADE
通过血管紧张素阻断减少二尖瓣关闭不全
- 批准号:
7206100 - 财政年份:2005
- 资助金额:
$ 74.26万 - 项目类别:
Mitral Insufficiency Reduction by Angiotensin Blockade
通过血管紧张素阻断减少二尖瓣关闭不全
- 批准号:
7042305 - 财政年份:2003
- 资助金额:
$ 74.26万 - 项目类别:
ANGIOTENSIN-II BLOCKADE IN MITRAL REGURGITATION
血管紧张素 II 阻断治疗二尖瓣反流
- 批准号:
6537825 - 财政年份:2001
- 资助金额:
$ 74.26万 - 项目类别:
ANGIOTENSIN-II BLOCKADE IN MITRAL REGURGITATION
血管紧张素 II 阻断治疗二尖瓣反流
- 批准号:
6638656 - 财政年份:2001
- 资助金额:
$ 74.26万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
Operating Grants














{{item.name}}会员




